Loading clinical trials...
Loading clinical trials...
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Conditions
Interventions
SPN-812
Locations
38
United States
South California Research LLC
Beverly Hills, California, United States
Collaborative Neuroscience Network
Garden Grove, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
Artemis Research Institue for Clinical Research
Riverside, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Start Date
January 23, 2020
Primary Completion Date
July 26, 2022
Completion Date
December 14, 2022
Last Updated
February 13, 2024
NCT06967857
NCT06577779
NCT07379359
NCT06798337
NCT07044609
NCT05778526
Lead Sponsor
Supernus Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions